Evidence map›Paper›PMID 25403208›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Prognosis and conditional disease-free survival among patients with ovarian cancer.

Michelle L Kurta, Robert P Edwards, Kirsten B Moysich, Kathleen McDonough, Marnie Bertolet, Joel L Weissfeld, Janet M Catov, Francesmary Modugno, Clareann H Bunker, Roberta B Ness and 1 more

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michelle L KurtaMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Robert P EdwardsMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Kirsten B MoysichMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Kathleen McDonoughMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Marnie BertoletMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Joel L WeissfeldMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Janet M CatovMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Francesmary ModugnoMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Clareann H BunkerMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Roberta B NessMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX.
Brenda DiergaardeMichelle L. Kurta, Marnie Bertolet, Joel L. Weissfeld, Janet M. Catov, Francesmary Modugno, Clareann H. Bunker, Brenda Diergaarde, Graduate School of Public Health; Marnie Bertolet, Clinical & Translational Science Institute, University of Pittsburgh; Robert P. Edwards, Kathleen McDonough, Joel L. Weissfeld, Brenda Diergaarde, University of Pittsburgh Cancer Institute; Robert P. Edwards, Janet M. Catov, Francesmary Modugno, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine; Robert P. Edwards, Francesmary Modugno, Magee-Womens Research Institute Ovarian Cancer Center of Excellence, Pittsburgh, PA; Kirsten B. Moysich, Roswell Park Cancer Institute, Buffalo, NY; and Roberta B. Ness, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX. diergaardeb@upmc.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Regulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
EDUCATION PROGRAMS IN CANCER PREVENTIONR25CA057703 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WEISSFELD, JOEL L · 1992 to 2010
$2.1M
NCATS NIH HHS UL1 TR000005NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA126841NCI NIH HHS R01CA126841NCI NIH HHS R25 CA057703NCI NIH HHS R25CA057703
6 · The paper itself

Abstract

purposeTraditional disease-free survival (DFS) does not reflect changes in prognosis over time. Conditional DFS accounts for elapsed time since achieving remission and may provide more relevant prognostic information for patients and clinicians. This study aimed to estimate conditional DFS among patients with ovarian cancer and to evaluate the impact of patient characteristics. PATIENTS AND

methodsPatients were recruited as part of the Hormones and Ovarian Cancer Prediction case-control study and were included in the current study if they had achieved remission after a diagnosis of cancer of the ovary, fallopian tube, or peritoneum (N = 404). Demographic and lifestyle information was collected at enrollment; disease, treatment, and outcome information was abstracted from medical records. DFS was calculated using the Kaplan-Meier method. Conditional DFS estimates were computed using cumulative DFS estimates.

resultsMedian DFS was 2.54 years (range, 0.03-9.96 years) and 3-year DFS was 48.2%. The probability of surviving an additional 3 years without recurrence, conditioned on having already survived 1, 2, 3, 4, and 5 years after remission, was 63.8%, 80.5%, 90.4%, 97.0%, and 97.7%, respectively. Initial differences in 3-year DFS at time of remission between age, stage, histology, and grade groups decreased over time.

conclusionDFS estimates for patients with ovarian cancer improved dramatically over time, in particular among those with poorer initial prognoses. Conditional DFS is a more relevant measure of prognosis for patients with ovarian cancer who have already achieved a period of remission, and time elapsed since remission should be taken into account when making follow-up care decisions.

Indexed as

AdultAgedCA-125 AntigenDisease-Free SurvivalFemaleHumansMiddle AgedOvarian NeoplasmsPrognosisProportional Hazards ModelsCA-125 Antigen

Identifiers

PMID25403208
PMCPMC4265120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.